Moreover, the steeper decline of MDRS in PD-GBA1 treated with STN-DBS does not directly reflect the onset of mild cognitive impairment or dementia, and the clinical implication of this computational analysis remains to be clarified. This evidence concerns the gene GBA1 and Parkinson disease.